AstraZeneca Plc (NASDAQ:AZN) on Monday posted mixed second-quarter 2026 results, beating Wall Street's earnings estimates while falling short on revenue.
The drugmaker also reported disappointing late-stage trial results for two experimental therapies, including a Phase 3 study of Ultomiris.
AstraZeneca Beats Earnings Estimates, Misses Revenue Expectations The company posted revenue of $15.384 billion, up 6% year over year, or 5% at constant currency (CC), missing the consensus estimate of $15.459 billion.
Adjusted earnings came in at $2.63 per share, ahead of expectations of $2.48.
AstraZeneca's oncology portfolio accounted for 48% of product revenue, rising 16% year over year, or 15% CC, to $7.33 billion.
